Luye Pharma Group (HKG:2186) enrolled the first patient in LY03015 for the Phase II clinical trial in China, according to a Wednesday filing with the Hong Kong Stock Exchange.
The drug is a next-generation VMAT2 inhibitor designed to treat tardive dyskinesia (TD) and Huntington's disease (HD).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.